BRAF inhibition and beyond in advanced melanoma
Mené sur 250 patients atteints d'un mélanome métastatique présentant la mutation V600E du gène BRAF, cet essai de phase III évalue, du point de vue de la survie sans progression, le dabrafenib par comparaison avec la dacarbazine
In The Lancet , Axel Hauschild and colleagues report results of a phase 3 trial of dabrafenib, an oral inhibitor of mutant BRAF, for the treatment of advanced melanoma. Adult patients with previously untreated, stage IV or unresectable stage III BRAF V600E mutation-positive melanoma were enrolled at centres in 12 countries; 187 were assigned dabrafenib (150 mg twice daily) and 63 were assigned intravenous dacarbazine (1000 mg/m 2 every 3 weeks).
Dabrafenib improved progression-free survival compared with ...
The Lancet , commentaire, 2011